vs
Paylocity Holding Corp（PCTY）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revvityの直近四半期売上が大きい（$772.1M vs $387.0M、Paylocity Holding Corpの約2.0倍）。Paylocity Holding Corpの純利益率が高く（13.0% vs 12.7%、差は0.2%）。Paylocity Holding Corpの前年同期比売上増加率が高い（11.3% vs 5.9%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $113.6M）。過去8四半期でRevvityの売上複合成長率が高い（9.0% vs 2.7%）
Paylocity Holding Corporationは米国発のクラウド型人事管理ソリューションプロバイダーで、給与計算、支出管理、人的資本管理（HCM）ソフトウェアを提供しています。様々な規模の企業の人事・財務関連業務の効率化とコスト削減を支援しています。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
PCTY vs RVTY — 直接比較
損益計算書 — Q2 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $387.0M | $772.1M |
| 純利益 | $50.2M | $98.4M |
| 粗利率 | 72.9% | — |
| 営業利益率 | 18.2% | 14.5% |
| 純利益率 | 13.0% | 12.7% |
| 売上前年比 | 11.3% | 5.9% |
| 純利益前年比 | 34.0% | 3.9% |
| EPS（希薄化後） | $0.92 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $387.0M | $772.1M | ||
| Q3 25 | $378.9M | $698.9M | ||
| Q2 25 | $369.9M | $720.3M | ||
| Q1 25 | $421.1M | $664.8M | ||
| Q4 24 | $347.7M | $729.4M | ||
| Q3 24 | $333.1M | $684.0M | ||
| Q2 24 | $324.7M | $691.7M | ||
| Q1 24 | $366.8M | $649.9M |
| Q4 25 | $50.2M | $98.4M | ||
| Q3 25 | $48.0M | $46.7M | ||
| Q2 25 | $48.6M | $53.9M | ||
| Q1 25 | $91.5M | $42.2M | ||
| Q4 24 | $37.5M | $94.6M | ||
| Q3 24 | $49.6M | $94.4M | ||
| Q2 24 | $48.8M | $55.4M | ||
| Q1 24 | $85.3M | $26.0M |
| Q4 25 | 72.9% | — | ||
| Q3 25 | 73.9% | 53.6% | ||
| Q2 25 | 73.5% | 54.5% | ||
| Q1 25 | 77.1% | 56.5% | ||
| Q4 24 | 72.6% | — | ||
| Q3 24 | 74.4% | 56.3% | ||
| Q2 24 | 74.0% | 55.7% | ||
| Q1 24 | 77.8% | 54.6% |
| Q4 25 | 18.2% | 14.5% | ||
| Q3 25 | 19.6% | 11.7% | ||
| Q2 25 | 17.9% | 12.6% | ||
| Q1 25 | 30.2% | 10.9% | ||
| Q4 24 | 13.4% | 16.3% | ||
| Q3 24 | 19.3% | 14.3% | ||
| Q2 24 | 19.4% | 12.4% | ||
| Q1 24 | 29.0% | 6.8% |
| Q4 25 | 13.0% | 12.7% | ||
| Q3 25 | 12.7% | 6.7% | ||
| Q2 25 | 13.1% | 7.5% | ||
| Q1 25 | 21.7% | 6.4% | ||
| Q4 24 | 10.8% | 13.0% | ||
| Q3 24 | 14.9% | 13.8% | ||
| Q2 24 | 15.0% | 8.0% | ||
| Q1 24 | 23.3% | 4.0% |
| Q4 25 | $0.92 | $0.86 | ||
| Q3 25 | $0.86 | $0.40 | ||
| Q2 25 | $0.87 | $0.46 | ||
| Q1 25 | $1.61 | $0.35 | ||
| Q4 24 | $0.66 | $0.77 | ||
| Q3 24 | $0.88 | $0.77 | ||
| Q2 24 | $0.85 | $0.45 | ||
| Q1 24 | $1.50 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $162.5M | $919.9M |
| 総負債低いほど良い | $81.3M | — |
| 株主資本純資産 | $1.1B | $7.3B |
| 総資産 | $7.0B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.07× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $162.5M | $919.9M | ||
| Q3 25 | $165.2M | $931.4M | ||
| Q2 25 | $398.1M | $991.8M | ||
| Q1 25 | $477.8M | $1.1B | ||
| Q4 24 | $482.4M | $1.2B | ||
| Q3 24 | $778.5M | $1.2B | ||
| Q2 24 | $401.8M | $2.0B | ||
| Q1 24 | $492.7M | $1.7B |
| Q4 25 | $81.3M | — | ||
| Q3 25 | $81.3M | — | ||
| Q2 25 | $162.5M | — | ||
| Q1 25 | $243.8M | — | ||
| Q4 24 | $325.0M | — | ||
| Q3 24 | $325.0M | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.1B | $7.3B | ||
| Q3 25 | $1.1B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.2B | $7.6B | ||
| Q4 24 | $1.2B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.0B | $7.9B | ||
| Q1 24 | $1.1B | $7.8B |
| Q4 25 | $7.0B | $12.2B | ||
| Q3 25 | $4.2B | $12.1B | ||
| Q2 25 | $4.4B | $12.4B | ||
| Q1 25 | $5.2B | $12.4B | ||
| Q4 24 | $5.3B | $12.4B | ||
| Q3 24 | $4.0B | $12.8B | ||
| Q2 24 | $4.2B | $13.4B | ||
| Q1 24 | $5.0B | $13.4B |
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.07× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.20× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.29× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $117.0M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $113.6M | $161.8M |
| FCFマージンFCF / 売上 | 29.4% | 21.0% |
| 設備投資強度設備投資 / 売上 | 0.9% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 2.33× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $461.1M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $117.0M | $182.0M | ||
| Q3 25 | $86.5M | $138.5M | ||
| Q2 25 | $86.6M | $134.3M | ||
| Q1 25 | $186.0M | $128.2M | ||
| Q4 24 | $54.2M | $174.2M | ||
| Q3 24 | $91.5M | $147.9M | ||
| Q2 24 | $79.9M | $158.6M | ||
| Q1 24 | $167.5M | $147.6M |
| Q4 25 | $113.6M | $161.8M | ||
| Q3 25 | $82.7M | $120.0M | ||
| Q2 25 | $81.1M | $115.5M | ||
| Q1 25 | $183.7M | $112.2M | ||
| Q4 24 | $51.2M | $149.8M | ||
| Q3 24 | $89.1M | $125.6M | ||
| Q2 24 | $73.6M | $136.6M | ||
| Q1 24 | $162.0M | $129.7M |
| Q4 25 | 29.4% | 21.0% | ||
| Q3 25 | 21.8% | 17.2% | ||
| Q2 25 | 21.9% | 16.0% | ||
| Q1 25 | 43.6% | 16.9% | ||
| Q4 24 | 14.7% | 20.5% | ||
| Q3 24 | 26.8% | 18.4% | ||
| Q2 24 | 22.7% | 19.7% | ||
| Q1 24 | 44.2% | 20.0% |
| Q4 25 | 0.9% | 2.6% | ||
| Q3 25 | 1.0% | 2.6% | ||
| Q2 25 | 1.5% | 2.6% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 0.9% | 3.4% | ||
| Q3 24 | 0.7% | 3.3% | ||
| Q2 24 | 1.9% | 3.2% | ||
| Q1 24 | 1.5% | 2.7% |
| Q4 25 | 2.33× | 1.85× | ||
| Q3 25 | 1.80× | 2.97× | ||
| Q2 25 | 1.78× | 2.49× | ||
| Q1 25 | 2.03× | 3.03× | ||
| Q4 24 | 1.45× | 1.84× | ||
| Q3 24 | 1.84× | 1.57× | ||
| Q2 24 | 1.64× | 2.87× | ||
| Q1 24 | 1.96× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PCTY
| Recurring Fees | $370.1M | 96% |
| Implementation Services And Other | $16.9M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
